Fidock D A, Pasquetto V, Gras H, Badell E, Eling W, Ballou W R, Belghiti J, Tartar A, Druilhe P
Laboratoire de Parasitologie Bio-Médicale, Institut Pasteur, Paris, France.
Eur J Immunol. 1997 Oct;27(10):2502-13. doi: 10.1002/eji.1830271007.
Antibody(Ab)-mediated inhibition of sporozoite invasion of hepatocytes is a mechanism that has been clearly demonstrated to act upon Plasmodium falciparum pre-erythrocytic stages in humans. Consequently we have analyzed the Ab response to a recently identified P. falciparum sporozoite surface protein, STARP, in malaria-exposed individuals and tested the inhibitory effect of these Ab upon hepatocyte invasion in vitro. STARP-specific IgG were detected in 90 and 61% of sera from regions where individuals were exposed to 100 and 1-5 infectious bites per year, respectively. These IgG were predominantly of the cytophilic IgG1 or IgG3 type. STARP and the major sporozoite surface protein, CS, elicited equivalent IgG levels in adults. When affinity purified from either African immune sera or the serum of an individual experimentally protected by irradiated sporozoite immunization, STARP-specific Ab prevented up to 90% of sporozoites from invading human hepatocytes. The dose-dependent and reproducible inhibition was more pronounced than that observed with human CS-specific Ab affinity purified under identical conditions. Substantial reduction of sporozoite invasion was also observed with Ab induced by artificial immunization with recombinant STARP protein and reactive with the native protein. Taken together with recent findings of human cytotoxic T lymphocytes specific for this antigen, these results promote the interest of studying the efficacy of STARP as a target for immune effector mechanisms operating upon pre-erythrocytic stages.
抗体(Ab)介导的对疟原虫子孢子侵入肝细胞的抑制作用是一种已被明确证明作用于人类恶性疟原虫红细胞前期阶段的机制。因此,我们分析了疟疾暴露个体对最近鉴定出的恶性疟原虫子孢子表面蛋白STARP的抗体反应,并在体外测试了这些抗体对肝细胞侵入的抑制作用。在每年分别暴露于100次和1 - 5次感染性叮咬的地区,90%和61%的血清中检测到了STARP特异性IgG。这些IgG主要是亲细胞性的IgG1或IgG3型。在成年人中,STARP和主要的子孢子表面蛋白CS引发了相当的IgG水平。当从非洲免疫血清或经辐照子孢子免疫实验性保护的个体血清中亲和纯化时,STARP特异性抗体可阻止高达90%的子孢子侵入人肝细胞。这种剂量依赖性和可重复性的抑制作用比在相同条件下亲和纯化的人CS特异性抗体所观察到的更为明显。用重组STARP蛋白人工免疫诱导并与天然蛋白反应的抗体也观察到子孢子侵入的显著减少。结合最近关于针对该抗原的人类细胞毒性T淋巴细胞的研究结果,这些结果激发了研究STARP作为红细胞前期阶段免疫效应机制靶点的功效的兴趣。